Status:
COMPLETED
A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
Lead Sponsor:
Achieve Life Sciences
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This clinical study will help determine if giving OGX-011 (custirsen sodium) in combination with gemcitabine (GEM) and cisplatin (CIS) or carboplatin (CARB) is a safe and effective treatment for patie...
Detailed Description
OGX-011 is an experimental drug that has been shown to increase the effectiveness of commonly used cancer therapies such as chemotherapy, radiation and hormone therapy in several kinds of cancer types...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Patients must have a histologically or cytologically confirmed diagnosis of NSCLC and must not have had chemotherapy or biological therapy for their disease.
- Stage IIIB (N3 and/or pleural or pericardial effusion) or IV disease that is not amenable to either surgery or radiation therapy of curative intent.
- Life expectancy of ≥ 12 weeks
- If patient has had prior radiation therapy: lesion(s) used for determination of response was not previously irradiated or has increased in size since the completion of radiotherapy; and patient has recovered from any toxicity from the radiotherapy.
- Radiotherapy to lesion(s) used for determination of response was completed at least 6 weeks prior to treatment; radiotherapy to other sites was completed at least 2 weeks prior to treatment.
- At least one unidimensionally measurable lesion meeting Response Evaluation Criteria in Solid Tumors \[RECIST\] (at least 10 mm in longest diameter by spiral computed tomography \[CT\] scan, or at least 20 mm by standard techniques).
- ECOG status must be ≤ 1
- Exclusion Criteria
- Prior chemotherapy or biological therapy (approved or experimental) for NSCLC, including adjuvant and neoadjuvant treatment.
- Presence of central nervous system (CNS) metastases, unless the patient has completed successful local therapy for CNS metastases, with the exception of leptomeningeal disease for which patients will be excluded. Patients must be off corticosteroids for at least 21 days prior to starting treatment.
- Second primary malignancy (except in situ carcinoma of the cervix, adequately treated non-melanomatous skin cancers, clinically localized prostate cancer, superficial bladder cancer or other malignancy treated at least 3 years previously with no evidence of recurrence).
- Patients eligible for combined modality therapy with curative intent as defined by the combination of chemotherapy, radiation therapy and/or surgery. (This criteria is intended to exclude patients with stage IIIB disease, as defined by the presence of N3 nodal status, who have been reported to have cure rates as high as 10% when treated with combined modality therapy.)
Exclusion
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
85 Patients enrolled
Trial Details
Trial ID
NCT00138658
Start Date
November 1 2004
End Date
March 1 2010
Last Update
February 6 2012
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
LAC-USC Medical Center
Los Angeles, California, United States, 90033
2
University of Southern California Norris
Los Angeles, California, United States, 90033
3
New York Oncology Hematology
Albany, New York, United States, 12208
4
Oregon Health and Science University
Portland, Oregon, United States, 97239